Effect of silodosin on detrusor overactivity in the male spontaneously hypertensive rat

What's known on the subject? and What does the study add? Recently, several studies have suggested that detrusor overactivity (DO) is the result of bladder ischaemia. Hypertension could affect pelvic arterial blood flow, resulting in loss of smooth muscle in the bladder with resultant loss of b...

Full description

Saved in:
Bibliographic Details
Published inBJU international Vol. 110; no. 2b; pp. E118 - E124
Main Authors Inoue, Seiya, Saito, Motoaki, Tsounapi, Panagiota, Dimitriadis, Fotios, Ohmasa, Fumiya, Kinoshita, Yukako, Satoh, Keisuke, Takenaka, Atsushi
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.07.2012
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract What's known on the subject? and What does the study add? Recently, several studies have suggested that detrusor overactivity (DO) is the result of bladder ischaemia. Hypertension could affect pelvic arterial blood flow, resulting in loss of smooth muscle in the bladder with resultant loss of bladder compliance. Spontaneously hypertensive rats are considered a valuable tool for exploring the pathogenesis of DO. Some reports indicate that α1 adrenoceptor antagonists improve chronic ischaemia of the lower urinary tract in patients with LUTS, with concomitant improvement of their symptoms as well as improvement of DO through an increased bladder blood flow (BBF) in the rat with bladder outlet obstruction. However, the mechanism of improvement of silodosin on storage or irritative symptoms is not well investigated and is still unclear. Silodosin prevents hypertension‐related DO in the SHR via several possible mechanisms. One possible mechanism of the efficacy of silodosin to the DO includes the improvement of the BBF. OBJECTIVE •  To investigate the effect of the α1A selective adrenoceptor antagonist, silodosin, on hypertension‐related detrusor overactivity (DO) and its possible mechanism in spontaneously hypertensive rats (SHRs). MATERIALS AND METHODS •  Twelve‐week‐old male SHRs received treatment with silodosin (100 µg/kg perorally) once daily for 6 weeks; vehicle‐treated Wistar rats and vehicle‐treated SHRs were used for our study. •  Six weeks after silodosin treatment, voiding functions were estimated by voiding behaviour and cystometric studies in all groups. •  The bladder blood flow was measured by the hydrogen clearance method, and tissue levels of nerve growth factor (NGF) and calcitonin gene‐related peptide (CGRP) were measured by enzyme‐linked immunosorbent assay (ELISA). •  Furthermore, the expressions of α1 adrenoceptor subtype mRNAs in the bladder were investigated by real‐time PCR method. RESULTS •  The SHRs showed significant increases in blood pressure, micturition frequency and tissue levels of NGF and CGRP in the bladder. •  Moreover, the SHRs showed significant decreases in bladder blood flow and single voided volume estimated by both voiding behaviour and cystometric studies compared with those in the Wistar rats. •  Six weeks of treatment with silodosin significantly ameliorated hypertension‐related alterations of these variables with concomitant small changes of blood pressure. •  The expression levels of α1 adrenoceptor subtype mRNAs in the bladder were similar in all the groups and the rank order was α1A =α1D > α1B in all groups. •  However, there were no significant differences in the expressions of α1A adrenoceptor mRNAs between any groups. CONCLUSION •  The data in the present study suggest that silodosin normalizes hypertension‐related DO in SHRs, which could be related to its effect on the increased blood flow in the bladder.
AbstractList UNLABELLEDRecently, several studies have suggested that detrusor overactivity (DO) is the result of bladder ischaemia. Hypertension could affect pelvic arterial blood flow, resulting in loss of smooth muscle in the bladder with resultant loss of bladder compliance. Spontaneously hypertensive rats are considered a valuable tool for exploring the pathogenesis of DO. Some reports indicate that α(1) adrenoceptor antagonists improve chronic ischaemia of the lower urinary tract in patients with LUTS, with concomitant improvement of their symptoms as well as improvement of DO through an increased bladder blood flow (BBF) in the rat with bladder outlet obstruction. However, the mechanism of improvement of silodosin on storage or irritative symptoms is not well investigated and is still unclear. Silodosin prevents hypertension-related DO in the SHR via several possible mechanisms. One possible mechanism of the efficacy of silodosin to the DO includes the improvement of the BBF.OBJECTIVETo investigate the effect of the α(1A) selective adrenoceptor antagonist, silodosin, on hypertension-related detrusor overactivity (DO) and its possible mechanism in spontaneously hypertensive rats (SHRs).MATERIALS AND METHODSTwelve-week-old male SHRs received treatment with silodosin (100 µg/kg perorally) once daily for 6 weeks; vehicle-treated Wistar rats and vehicle-treated SHRs were used for our study. Six weeks after silodosin treatment, voiding functions were estimated by voiding behaviour and cystometric studies in all groups. The bladder blood flow was measured by the hydrogen clearance method, and tissue levels of nerve growth factor (NGF) and calcitonin gene-related peptide (CGRP) were measured by enzyme-linked immunosorbent assay (ELISA). Furthermore, the expressions of α1 adrenoceptor subtype mRNAs in the bladder were investigated by real-time PCR method.RESULTSThe SHRs showed significant increases in blood pressure, micturition frequency and tissue levels of NGF and CGRP in the bladder. Moreover, the SHRs showed significant decreases in bladder blood flow and single voided volume estimated by both voiding behaviour and cystometric studies compared with those in the Wistar rats. Six weeks of treatment with silodosin significantly ameliorated hypertension-related alterations of these variables with concomitant small changes of blood pressure. The expression levels of α1 adrenoceptor subtype mRNAs in the bladder were similar in all the groups and the rank order was α1A = α1D > α1B in all groups. However, there were no significant differences in the expressions of α(1A) adrenoceptor mRNAs between any groups.CONCLUSIONThe data in the present study suggest that silodosin normalizes hypertension-related DO in SHRs, which could be related to its effect on the increased blood flow in the bladder.
What's known on the subject? and What does the study add? Recently, several studies have suggested that detrusor overactivity (DO) is the result of bladder ischaemia. Hypertension could affect pelvic arterial blood flow, resulting in loss of smooth muscle in the bladder with resultant loss of bladder compliance. Spontaneously hypertensive rats are considered a valuable tool for exploring the pathogenesis of DO. Some reports indicate that α 1 adrenoceptor antagonists improve chronic ischaemia of the lower urinary tract in patients with LUTS, with concomitant improvement of their symptoms as well as improvement of DO through an increased bladder blood flow (BBF) in the rat with bladder outlet obstruction. However, the mechanism of improvement of silodosin on storage or irritative symptoms is not well investigated and is still unclear. Silodosin prevents hypertension‐related DO in the SHR via several possible mechanisms. One possible mechanism of the efficacy of silodosin to the DO includes the improvement of the BBF. OBJECTIVE To investigate the effect of the α 1A selective adrenoceptor antagonist, silodosin, on hypertension‐related detrusor overactivity (DO) and its possible mechanism in spontaneously hypertensive rats (SHRs). MATERIALS AND METHODS Twelve‐week‐old male SHRs received treatment with silodosin (100 µg/kg perorally) once daily for 6 weeks; vehicle‐treated Wistar rats and vehicle‐treated SHRs were used for our study. Six weeks after silodosin treatment, voiding functions were estimated by voiding behaviour and cystometric studies in all groups. The bladder blood flow was measured by the hydrogen clearance method, and tissue levels of nerve growth factor (NGF) and calcitonin gene‐related peptide (CGRP) were measured by enzyme‐linked immunosorbent assay (ELISA). Furthermore, the expressions of α1 adrenoceptor subtype mRNAs in the bladder were investigated by real‐time PCR method. RESULTS The SHRs showed significant increases in blood pressure, micturition frequency and tissue levels of NGF and CGRP in the bladder. Moreover, the SHRs showed significant decreases in bladder blood flow and single voided volume estimated by both voiding behaviour and cystometric studies compared with those in the Wistar rats. Six weeks of treatment with silodosin significantly ameliorated hypertension‐related alterations of these variables with concomitant small changes of blood pressure. The expression levels of α1 adrenoceptor subtype mRNAs in the bladder were similar in all the groups and the rank order was α1A =α1D > α1B in all groups. However, there were no significant differences in the expressions of α 1A adrenoceptor mRNAs between any groups. CONCLUSION The data in the present study suggest that silodosin normalizes hypertension‐related DO in SHRs, which could be related to its effect on the increased blood flow in the bladder.
What's known on the subject? and What does the study add? Recently, several studies have suggested that detrusor overactivity (DO) is the result of bladder ischaemia. Hypertension could affect pelvic arterial blood flow, resulting in loss of smooth muscle in the bladder with resultant loss of bladder compliance. Spontaneously hypertensive rats are considered a valuable tool for exploring the pathogenesis of DO. Some reports indicate that α1 adrenoceptor antagonists improve chronic ischaemia of the lower urinary tract in patients with LUTS, with concomitant improvement of their symptoms as well as improvement of DO through an increased bladder blood flow (BBF) in the rat with bladder outlet obstruction. However, the mechanism of improvement of silodosin on storage or irritative symptoms is not well investigated and is still unclear. Silodosin prevents hypertension‐related DO in the SHR via several possible mechanisms. One possible mechanism of the efficacy of silodosin to the DO includes the improvement of the BBF. OBJECTIVE •  To investigate the effect of the α1A selective adrenoceptor antagonist, silodosin, on hypertension‐related detrusor overactivity (DO) and its possible mechanism in spontaneously hypertensive rats (SHRs). MATERIALS AND METHODS •  Twelve‐week‐old male SHRs received treatment with silodosin (100 µg/kg perorally) once daily for 6 weeks; vehicle‐treated Wistar rats and vehicle‐treated SHRs were used for our study. •  Six weeks after silodosin treatment, voiding functions were estimated by voiding behaviour and cystometric studies in all groups. •  The bladder blood flow was measured by the hydrogen clearance method, and tissue levels of nerve growth factor (NGF) and calcitonin gene‐related peptide (CGRP) were measured by enzyme‐linked immunosorbent assay (ELISA). •  Furthermore, the expressions of α1 adrenoceptor subtype mRNAs in the bladder were investigated by real‐time PCR method. RESULTS •  The SHRs showed significant increases in blood pressure, micturition frequency and tissue levels of NGF and CGRP in the bladder. •  Moreover, the SHRs showed significant decreases in bladder blood flow and single voided volume estimated by both voiding behaviour and cystometric studies compared with those in the Wistar rats. •  Six weeks of treatment with silodosin significantly ameliorated hypertension‐related alterations of these variables with concomitant small changes of blood pressure. •  The expression levels of α1 adrenoceptor subtype mRNAs in the bladder were similar in all the groups and the rank order was α1A =α1D > α1B in all groups. •  However, there were no significant differences in the expressions of α1A adrenoceptor mRNAs between any groups. CONCLUSION •  The data in the present study suggest that silodosin normalizes hypertension‐related DO in SHRs, which could be related to its effect on the increased blood flow in the bladder.
Recently, several studies have suggested that detrusor overactivity (DO) is the result of bladder ischaemia. Hypertension could affect pelvic arterial blood flow, resulting in loss of smooth muscle in the bladder with resultant loss of bladder compliance. Spontaneously hypertensive rats are considered a valuable tool for exploring the pathogenesis of DO. Some reports indicate that α(1) adrenoceptor antagonists improve chronic ischaemia of the lower urinary tract in patients with LUTS, with concomitant improvement of their symptoms as well as improvement of DO through an increased bladder blood flow (BBF) in the rat with bladder outlet obstruction. However, the mechanism of improvement of silodosin on storage or irritative symptoms is not well investigated and is still unclear. Silodosin prevents hypertension-related DO in the SHR via several possible mechanisms. One possible mechanism of the efficacy of silodosin to the DO includes the improvement of the BBF. To investigate the effect of the α(1A) selective adrenoceptor antagonist, silodosin, on hypertension-related detrusor overactivity (DO) and its possible mechanism in spontaneously hypertensive rats (SHRs). Twelve-week-old male SHRs received treatment with silodosin (100 µg/kg perorally) once daily for 6 weeks; vehicle-treated Wistar rats and vehicle-treated SHRs were used for our study. Six weeks after silodosin treatment, voiding functions were estimated by voiding behaviour and cystometric studies in all groups. The bladder blood flow was measured by the hydrogen clearance method, and tissue levels of nerve growth factor (NGF) and calcitonin gene-related peptide (CGRP) were measured by enzyme-linked immunosorbent assay (ELISA). Furthermore, the expressions of α1 adrenoceptor subtype mRNAs in the bladder were investigated by real-time PCR method. The SHRs showed significant increases in blood pressure, micturition frequency and tissue levels of NGF and CGRP in the bladder. Moreover, the SHRs showed significant decreases in bladder blood flow and single voided volume estimated by both voiding behaviour and cystometric studies compared with those in the Wistar rats. Six weeks of treatment with silodosin significantly ameliorated hypertension-related alterations of these variables with concomitant small changes of blood pressure. The expression levels of α1 adrenoceptor subtype mRNAs in the bladder were similar in all the groups and the rank order was α1A = α1D > α1B in all groups. However, there were no significant differences in the expressions of α(1A) adrenoceptor mRNAs between any groups. The data in the present study suggest that silodosin normalizes hypertension-related DO in SHRs, which could be related to its effect on the increased blood flow in the bladder.
What's known on the subject? and What does the study add? Recently, several studies have suggested that detrusor overactivity (DO) is the result of bladder ischaemia. Hypertension could affect pelvic arterial blood flow, resulting in loss of smooth muscle in the bladder with resultant loss of bladder compliance. Spontaneously hypertensive rats are considered a valuable tool for exploring the pathogenesis of DO. Some reports indicate that [alpha]1 adrenoceptor antagonists improve chronic ischaemia of the lower urinary tract in patients with LUTS, with concomitant improvement of their symptoms as well as improvement of DO through an increased bladder blood flow (BBF) in the rat with bladder outlet obstruction. However, the mechanism of improvement of silodosin on storage or irritative symptoms is not well investigated and is still unclear. Silodosin prevents hypertension-related DO in the SHR via several possible mechanisms. One possible mechanism of the efficacy of silodosin to the DO includes the improvement of the BBF. OBJECTIVE * To investigate the effect of the [alpha]1A selective adrenoceptor antagonist, silodosin, on hypertension-related detrusor overactivity (DO) and its possible mechanism in spontaneously hypertensive rats (SHRs). MATERIALS AND METHODS * Twelve-week-old male SHRs received treatment with silodosin (100µg/kg perorally) once daily for 6 weeks; vehicle-treated Wistar rats and vehicle-treated SHRs were used for our study. * Six weeks after silodosin treatment, voiding functions were estimated by voiding behaviour and cystometric studies in all groups. * The bladder blood flow was measured by the hydrogen clearance method, and tissue levels of nerve growth factor (NGF) and calcitonin gene-related peptide (CGRP) were measured by enzyme-linked immunosorbent assay (ELISA). * Furthermore, the expressions of [alpha]1 adrenoceptor subtype mRNAs in the bladder were investigated by real-time PCR method. RESULTS * The SHRs showed significant increases in blood pressure, micturition frequency and tissue levels of NGF and CGRP in the bladder. * Moreover, the SHRs showed significant decreases in bladder blood flow and single voided volume estimated by both voiding behaviour and cystometric studies compared with those in the Wistar rats. * Six weeks of treatment with silodosin significantly ameliorated hypertension-related alterations of these variables with concomitant small changes of blood pressure. * The expression levels of [alpha]1 adrenoceptor subtype mRNAs in the bladder were similar in all the groups and the rank order was [alpha]1A =[alpha]1D > [alpha]1B in all groups. * However, there were no significant differences in the expressions of [alpha]1A adrenoceptor mRNAs between any groups. CONCLUSION * The data in the present study suggest that silodosin normalizes hypertension-related DO in SHRs, which could be related to its effect on the increased blood flow in the bladder. [PUBLICATION ABSTRACT]
Author Inoue, Seiya
Takenaka, Atsushi
Saito, Motoaki
Tsounapi, Panagiota
Ohmasa, Fumiya
Satoh, Keisuke
Dimitriadis, Fotios
Kinoshita, Yukako
Author_xml – sequence: 1
  givenname: Seiya
  surname: Inoue
  fullname: Inoue, Seiya
– sequence: 2
  givenname: Motoaki
  surname: Saito
  fullname: Saito, Motoaki
– sequence: 3
  givenname: Panagiota
  surname: Tsounapi
  fullname: Tsounapi, Panagiota
– sequence: 4
  givenname: Fotios
  surname: Dimitriadis
  fullname: Dimitriadis, Fotios
– sequence: 5
  givenname: Fumiya
  surname: Ohmasa
  fullname: Ohmasa, Fumiya
– sequence: 6
  givenname: Yukako
  surname: Kinoshita
  fullname: Kinoshita, Yukako
– sequence: 7
  givenname: Keisuke
  surname: Satoh
  fullname: Satoh, Keisuke
– sequence: 8
  givenname: Atsushi
  surname: Takenaka
  fullname: Takenaka, Atsushi
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22146017$$D View this record in MEDLINE/PubMed
BookMark eNqNkMtOwzAQRS0Eorx-AVliw6bBE9tps0GCiqeQ2IBgZznORE2VxsV2Cvl73JayYIU3HvneuTM-h2S3tS0SQoElEM_FLAGRiaEA9p6kDCABNgaRfO2Qg19hd1uzPBuQQ-9njMWHTO6TQZrGisHogLzdVBWaQG1Ffd3Y0vq6pbalJQbXeeuoXaLTJtTLOvQ0amGKdK4bpH5h26BbtJ1vejrtF-gCtr5eInU6HJO9SjceT37uI_J6e_MyuR8-Pd89TK6ehkaCEENZVjmUHHQmmJFMgC5KRBBMliNpdAGGC6Ojoke6KgqRm_gbyQuep1mejZEfkfNN7sLZjw59UPPaG2yazWYKWJpKmaepiNazP9aZ7Vwbt1PAJZNS8BGPrvHGZZz13mGlFq6ea9fHKLWCr2ZqxVWtGKsVfLWGr75i6-nPgK6YY_nbuKUdDZcbw2fdYP_vYHX9-Lou-TcsiJVr
CODEN BJINFO
CitedBy_id crossref_primary_10_1016_j_niox_2022_07_004
crossref_primary_10_1111_iju_14478
crossref_primary_10_3390_metabo12050468
crossref_primary_10_1016_j_jphs_2016_08_007
crossref_primary_10_1016_j_juro_2013_03_110
crossref_primary_10_1111_iju_14171
crossref_primary_10_1007_s00210_015_1137_y
crossref_primary_10_1111_luts_12106
crossref_primary_10_1186_s12894_017_0256_9
crossref_primary_10_1002_nau_24440
crossref_primary_10_1254_fpj_19135
crossref_primary_10_1002_nau_22405
crossref_primary_10_1007_s11255_019_02222_1
crossref_primary_10_1111_iju_12501
crossref_primary_10_1371_journal_pone_0133798
crossref_primary_10_1186_s12894_020_00699_y
crossref_primary_10_1111_iju_14502
crossref_primary_10_1016_j_urology_2018_07_008
crossref_primary_10_1016_j_ijpharm_2013_07_041
crossref_primary_10_1111_iju_12680
crossref_primary_10_1517_14728222_2015_1009447
crossref_primary_10_1007_s00345_014_1239_z
crossref_primary_10_1007_s00345_019_02939_9
crossref_primary_10_1016_j_jsxm_2016_10_005
crossref_primary_10_1146_annurev_pharmtox_010814_124536
crossref_primary_10_1007_s12325_018_0854_2
crossref_primary_10_1111_j_1757_5672_2012_00164_x
crossref_primary_10_1254_fpj_154_250
crossref_primary_10_1111_ijcp_12135
crossref_primary_10_1002_nau_23547
crossref_primary_10_1016_j_ejps_2020_105329
crossref_primary_10_1002_nau_23788
crossref_primary_10_1016_j_prnil_2023_09_003
Cites_doi 10.1016/j.juro.2008.08.002
10.1016/j.juro.2009.02.034
10.1159/000283068
10.1016/j.urology.2009.05.045
10.1016/j.ejphar.2004.08.005
10.1002/nau.20843
10.1016/S0022-5347(05)68995-1
10.1152/ajpregu.1998.275.4.R1366
10.1002/nau.20873
10.1016/S0140-6736(03)13073-5
10.1016/S0022-5347(05)00016-9
10.1124/mi.8.5.9
10.1016/S0094-0143(21)00671-6
10.1038/sj.bjc.6600296
10.1152/ajprenal.00553.2009
10.1016/j.rcl.2006.07.005
10.1038/sj.bjp.0701731
10.1002/nau.20312
10.1007/s00345-009-0481-2
10.1111/j.1464-410X.2007.07339.x
10.1002/nau.20984
10.1016/S0022-5347(05)68236-5
10.1111/j.1469-445X.1999.tb00079.x
10.1016/j.eururo.2010.10.046
10.1111/j.1757-5672.2011.00087.x
10.1111/j.1464-410X.2008.07587.x
10.1006/phrs.2001.0857
10.1016/j.lfs.2007.05.004
10.1046/j.1464-410X.1998.0820s1026.x
10.1161/01.RES.14.2.164
10.1016/S0891-0618(00)00115-0
10.1002/nau.10052
10.1016/S0022-5347(01)65075-4
10.1111/j.1464-410X.2006.06448.x
ContentType Journal Article
Copyright 2011 BJU INTERNATIONAL
2011 BJU INTERNATIONAL.
Copyright_xml – notice: 2011 BJU INTERNATIONAL
– notice: 2011 BJU INTERNATIONAL.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QP
7X8
DOI 10.1111/j.1464-410X.2011.10814.x
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Calcium & Calcified Tissue Abstracts
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Calcium & Calcified Tissue Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef

MEDLINE
Calcium & Calcified Tissue Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1464-410X
EndPage E124
ExternalDocumentID 2969314201
10_1111_j_1464_410X_2011_10814_x
22146017
BJU10814
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.3N
.55
.GA
.Y3
05W
0R~
10A
1OC
23N
24P
2WC
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
6P2
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABJNI
ABLJU
ABOCM
ABPVW
ABQWH
ABXGK
ACAHQ
ACCFJ
ACCZN
ACFBH
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFPWT
AFZJQ
AHBTC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BAWUL
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
E3Z
EAD
EAP
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
ESX
EX3
F00
F01
F04
F5P
FUBAC
G-S
G.N
GODZA
H.X
HF~
HGLYW
HZI
HZ~
IHE
IX1
J0M
J5H
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PQQKQ
Q.N
Q11
QB0
R.K
RJQFR
ROL
RX1
SUPJJ
SV3
TEORI
TUS
UB1
V9Y
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WRC
WVDHM
WXI
WXSBR
X7M
XG1
YFH
ZGI
ZXP
~IA
~WT
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QP
7X8
ID FETCH-LOGICAL-c5144-5df91d31a640c5041abdee1405d75cab1c34cac50a7afbb49c09653b3926968e3
IEDL.DBID DR2
ISSN 1464-4096
IngestDate Fri Aug 16 04:34:12 EDT 2024
Thu Oct 10 15:52:05 EDT 2024
Fri Aug 23 00:38:53 EDT 2024
Sat Sep 28 08:01:06 EDT 2024
Sat Aug 24 00:59:32 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2b
Language English
License 2011 BJU INTERNATIONAL.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5144-5df91d31a640c5041abdee1405d75cab1c34cac50a7afbb49c09653b3926968e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://doi.org/10.1111/j.1464-410x.2011.10814.x
PMID 22146017
PQID 1350554373
PQPubID 1026371
PageCount 7
ParticipantIDs proquest_miscellaneous_1022559224
proquest_journals_1350554373
crossref_primary_10_1111_j_1464_410X_2011_10814_x
pubmed_primary_22146017
wiley_primary_10_1111_j_1464_410X_2011_10814_x_BJU10814
PublicationCentury 2000
PublicationDate July 2012
PublicationDateYYYYMMDD 2012-07-01
PublicationDate_xml – month: 07
  year: 2012
  text: July 2012
PublicationDecade 2010
PublicationPlace Oxford, UK
PublicationPlace_xml – name: Oxford, UK
– name: England
– name: Edgecliff
PublicationTitle BJU international
PublicationTitleAlternate BJU Int
PublicationYear 2012
Publisher Blackwell Publishing Ltd
Wiley Subscription Services, Inc
Publisher_xml – name: Blackwell Publishing Ltd
– name: Wiley Subscription Services, Inc
References 1997; 157
2010; 75
2004; 501
2006; 98
2009; 181
2011; 30
1999; 162
2006; 175
2008; 8
2003; 19
1999; 84
2011; 59
1998; 82
2008; 102
2008; 101
2001; 44
1998; 275
2011; 3
2001; 21
2008; 180
2002; 86
2010; 29
2006; 44
2010; 28
1997; 59
1999; 161
2002; 21
2006; 25
2010; 299
1995; 22
2007; 81
1964; 14
1998; 123
e_1_2_7_5_2
e_1_2_7_4_2
e_1_2_7_3_2
e_1_2_7_2_2
e_1_2_7_9_2
e_1_2_7_8_2
e_1_2_7_7_2
e_1_2_7_6_2
e_1_2_7_19_2
e_1_2_7_18_2
e_1_2_7_17_2
e_1_2_7_16_2
e_1_2_7_15_2
e_1_2_7_14_2
e_1_2_7_13_2
e_1_2_7_12_2
e_1_2_7_11_2
e_1_2_7_10_2
Kuo HC (e_1_2_7_33_2) 2011; 3
e_1_2_7_26_2
e_1_2_7_27_2
e_1_2_7_28_2
e_1_2_7_29_2
Holtgrewe HL (e_1_2_7_30_2) 1995; 22
e_1_2_7_25_2
e_1_2_7_24_2
e_1_2_7_23_2
e_1_2_7_31_2
e_1_2_7_22_2
e_1_2_7_32_2
e_1_2_7_21_2
e_1_2_7_20_2
e_1_2_7_34_2
e_1_2_7_35_2
References_xml – volume: 175
  start-page: 358
  year: 2006
  end-page: 64
  article-title: Activation of alpha1D adrenergic receptors ih the rat urothelium facilitates the micturition reflex
  publication-title: J Urol
– volume: 84
  start-page: 137
  year: 1999
  end-page: 47
  article-title: The spontaneously hypertensive rat: insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males
  publication-title: Exp Physiol
– volume: 181
  start-page: 2634
  year: 2009
  end-page: 40
  article-title: Rapid efficacy of the highly selective alpha1A‐adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies
  publication-title: J Urol
– volume: 102
  start-page: 470
  year: 2008
  end-page: 4
  article-title: Association of lower urinary tract symptoms and chronic ischaemia of the lower urinary tract in elderly women and men: assessment using colour Doppler ultrasonography
  publication-title: BJU Int
– volume: 28
  start-page: 609
  year: 2010
  end-page: 14
  article-title: Selective α1A‐blocker improves bladder storage function in rats via suppression of C‐fiber afferent activity
  publication-title: World J Urol
– volume: 29
  start-page: 1350
  year: 2010
  end-page: 4
  article-title: The effects of chronic hyperlipidemia on bladder function in myocardial infarction‐prone Watanabe heritable hyperlipidemic (WHHLMI) rabbits
  publication-title: Neurourol Urodyn
– volume: 21
  start-page: 125
  year: 2001
  end-page: 38
  article-title: Alterrations in neuropeptide expression in lumbosacral pathways following chronic cyctitis
  publication-title: J Chem Neuroanat
– volume: 44
  start-page: 689
  year: 2006
  end-page: 710
  article-title: Benign prostatic hyperplasia: a review and ultrasound classification
  publication-title: Radiol Clin North Am
– volume: 44
  start-page: 195
  year: 2001
  end-page: 208
  article-title: Alpha‐adrenoceptor subtypes
  publication-title: Pharmacol Res
– volume: 59
  start-page: 342
  year: 2011
  end-page: 52
  article-title: Silodosin Therapy for Lower Urinary Tract Symptoms in Men with Suspected Benign Prostatic Hyperplasia: results of an International, Randomized, Double‐Blind, Placebo‐ and Active‐Controlled Clinical Trial Performed in Europe
  publication-title: Eur Urol
– volume: 59
  start-page: 226
  year: 1997
  end-page: 30
  article-title: Effects of partial outflow obstruction on bladder contractility and blood flow to the detrusor: comparison between mild and severe obstruction
  publication-title: Urol Int
– volume: 275
  start-page: 1366
  year: 1998
  end-page: 73
  article-title: Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats
  publication-title: Am J Physiol
– volume: 180
  start-page: 2701
  year: 2008
  end-page: 5
  article-title: Pharmacological properties, functional alterations and gene expression of muscarinic receptors in young and old type 2 Goto‐Kakizaki diabetic rat bladders
  publication-title: J Urol
– volume: 157
  start-page: 885
  year: 1997
  end-page: 9
  article-title: The International Continence Society ‘Benign Prostatic Hyperplasia’ Study: the botherosomeness of urinary symptoms
  publication-title: J Urol
– volume: 21
  start-page: 167
  year: 2002
  end-page: 78
  article-title: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub‐committee of the International Continence Society
  publication-title: Neurourol Urodyn
– volume: 25
  start-page: 792
  year: 2006
  end-page: 9
  article-title: Uroselectivity in male dogs of silodosin (KMD‐3213), a novel drug for the obstructive component of benign prostatic hyperplasia
  publication-title: Neurourol Urodyn
– volume: 19
  start-page: 1359
  year: 2003
  end-page: 67
  article-title: Benign prostatic hyperplasia
  publication-title: Lancet
– volume: 101
  start-page: 319
  year: 2008
  end-page: 24
  article-title: alpha‐Blockers improve chronic ischaemia of the lower urinary tract in patients with lower urinary tract symptoms
  publication-title: BJU Int
– volume: 98
  start-page: 1019
  year: 2006
  end-page: 24
  article-title: Silodosin, a new alpha1A‐adrenoceptor‐selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo‐controlled, double‐blind study in Japanese men
  publication-title: BJU Int
– volume: 30
  start-page: 461
  year: 2011
  end-page: 7
  article-title: Alpha1‐ adrenoceptor antagonists improve bladder storage function through reduction of afferent activity in rats with bladder outlet obstruction
  publication-title: Neurourol Urodyn
– volume: 82
  start-page: 26
  issue: 1
  year: 1998
  end-page: 33
  article-title: Age‐related erectile and voiding dysfunction: the role of arterial insufficiency
  publication-title: Br J Urol
– volume: 501
  start-page: 143
  year: 2004
  end-page: 9
  article-title: Effect of cyclohexenonic long‐chain fatty alcohol on rat overactive bladder induced by bladder neck obstruction
  publication-title: Eur J Pharmacol
– volume: 75
  start-page: 235
  year: 2010
  end-page: 40
  article-title: Effects of tamsulosin on bladder blood flow and bladder function in rats with bladder outlet obstruction
  publication-title: Urology
– volume: 14
  start-page: 164
  year: 1964
  end-page: 87
  article-title: Measurement of local blood flow with hydrogen gas
  publication-title: Circ Res
– volume: 123
  start-page: 1289
  year: 1998
  end-page: 93
  article-title: Quantification and distribution of alpha1‐adrenoceptor subtype mRNAs in human proximal urethra
  publication-title: Br J Pharmacol
– volume: 8
  start-page: 242
  year: 2008
  end-page: 53
  article-title: Inside information: the unique features of visceral sensation
  publication-title: Mol Interv
– volume: 162
  start-page: 1768
  year: 1999
  end-page: 78
  article-title: Overactivity and structural changes in the chronically ischemic bladder
  publication-title: J Urol
– volume: 86
  start-page: 1604
  year: 2002
  end-page: 14
  article-title: A novel combretastatin A‐4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs
  publication-title: Br J Cancer
– volume: 29
  start-page: 1338
  year: 2010
  end-page: 43
  article-title: Selection of a control rat for conscious spontaneous hypertensive rats in studies of detrusor overactivity on the basis of measurement of intra‐abdominal pressures
  publication-title: Neurourol Urodyn
– volume: 22
  start-page: 357
  year: 1995
  end-page: 68
  article-title: Transurethral prostatectomy
  publication-title: Urol Clin North Am
– volume: 81
  start-page: 218
  year: 2007
  end-page: 22
  article-title: Effects of doxazosin on blood flow and mRNA expression of nitric oxide synthase in the spontaneously hypertensive rat genitourinary tract
  publication-title: Life Sci
– volume: 161
  start-page: 1626
  year: 1999
  end-page: 35
  article-title: Atherosclerosis‐induced chronic ischemia causes bladder fibrosis and non‐compliance in the rabbit
  publication-title: J Urol
– volume: 299
  start-page: F785
  year: 2010
  end-page: 91
  article-title: Role of supraspinal and spinal alpha1‐adrenergic receptor subtypes in micturition reflex in conscious rats
  publication-title: Am J Physiol Renal Physiol
– volume: 3
  start-page: 2
  year: 2011
  end-page: 9
  article-title: Promise of urinary nerve growth factor for assessment of overactive bladder syndrome
  publication-title: LUTS
– ident: e_1_2_7_24_2
  doi: 10.1016/j.juro.2008.08.002
– ident: e_1_2_7_18_2
  doi: 10.1016/j.juro.2009.02.034
– ident: e_1_2_7_29_2
  doi: 10.1159/000283068
– ident: e_1_2_7_15_2
  doi: 10.1016/j.urology.2009.05.045
– ident: e_1_2_7_21_2
  doi: 10.1016/j.ejphar.2004.08.005
– ident: e_1_2_7_8_2
  doi: 10.1002/nau.20843
– ident: e_1_2_7_7_2
  doi: 10.1016/S0022-5347(05)68995-1
– ident: e_1_2_7_10_2
  doi: 10.1152/ajpregu.1998.275.4.R1366
– ident: e_1_2_7_20_2
  doi: 10.1002/nau.20873
– ident: e_1_2_7_4_2
  doi: 10.1016/S0140-6736(03)13073-5
– ident: e_1_2_7_25_2
  doi: 10.1016/S0022-5347(05)00016-9
– ident: e_1_2_7_34_2
  doi: 10.1124/mi.8.5.9
– volume: 22
  start-page: 357
  year: 1995
  ident: e_1_2_7_30_2
  article-title: Transurethral prostatectomy
  publication-title: Urol Clin North Am
  doi: 10.1016/S0094-0143(21)00671-6
  contributor:
    fullname: Holtgrewe HL
– ident: e_1_2_7_23_2
  doi: 10.1038/sj.bjc.6600296
– ident: e_1_2_7_26_2
  doi: 10.1152/ajprenal.00553.2009
– ident: e_1_2_7_3_2
  doi: 10.1016/j.rcl.2006.07.005
– ident: e_1_2_7_32_2
  doi: 10.1038/sj.bjp.0701731
– ident: e_1_2_7_16_2
  doi: 10.1002/nau.20312
– ident: e_1_2_7_27_2
  doi: 10.1007/s00345-009-0481-2
– ident: e_1_2_7_13_2
  doi: 10.1111/j.1464-410X.2007.07339.x
– ident: e_1_2_7_28_2
  doi: 10.1002/nau.20984
– ident: e_1_2_7_6_2
  doi: 10.1016/S0022-5347(05)68236-5
– ident: e_1_2_7_11_2
  doi: 10.1111/j.1469-445X.1999.tb00079.x
– ident: e_1_2_7_19_2
  doi: 10.1016/j.eururo.2010.10.046
– volume: 3
  start-page: 2
  year: 2011
  ident: e_1_2_7_33_2
  article-title: Promise of urinary nerve growth factor for assessment of overactive bladder syndrome
  publication-title: LUTS
  doi: 10.1111/j.1757-5672.2011.00087.x
  contributor:
    fullname: Kuo HC
– ident: e_1_2_7_14_2
  doi: 10.1111/j.1464-410X.2008.07587.x
– ident: e_1_2_7_31_2
  doi: 10.1006/phrs.2001.0857
– ident: e_1_2_7_12_2
  doi: 10.1016/j.lfs.2007.05.004
– ident: e_1_2_7_9_2
  doi: 10.1046/j.1464-410X.1998.0820s1026.x
– ident: e_1_2_7_22_2
  doi: 10.1161/01.RES.14.2.164
– ident: e_1_2_7_35_2
  doi: 10.1016/S0891-0618(00)00115-0
– ident: e_1_2_7_2_2
  doi: 10.1002/nau.10052
– ident: e_1_2_7_5_2
  doi: 10.1016/S0022-5347(01)65075-4
– ident: e_1_2_7_17_2
  doi: 10.1111/j.1464-410X.2006.06448.x
SSID ssj0014665
Score 2.2689714
Snippet What's known on the subject? and What does the study add? Recently, several studies have suggested that detrusor overactivity (DO) is the result of bladder...
Recently, several studies have suggested that detrusor overactivity (DO) is the result of bladder ischaemia. Hypertension could affect pelvic arterial blood...
What's known on the subject? and What does the study add? Recently, several studies have suggested that detrusor overactivity (DO) is the result of bladder...
UNLABELLEDRecently, several studies have suggested that detrusor overactivity (DO) is the result of bladder ischaemia. Hypertension could affect pelvic...
SourceID proquest
crossref
pubmed
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage E118
SubjectTerms Administration, Oral
Adrenergic beta-1 Receptor Antagonists - administration & dosage
Adrenergic beta-1 Receptor Antagonists - pharmacology
Animals
bladder blood flow
calcitonin gene‐related peptide (CGRP)
detrusor overactivity
Hypertension - complications
Indoles - administration & dosage
Indoles - pharmacology
Male
nerve growth factor (NGF)
Rats
Rats, Inbred SHR
Rats, Wistar
Receptors, Adrenergic, beta-1 - metabolism
RNA, Messenger - metabolism
SHR
silodosin
Urinary Bladder - blood supply
Urinary Bladder, Overactive - drug therapy
Urinary Bladder, Overactive - etiology
Urinary Bladder, Overactive - physiopathology
Urination - physiology
Title Effect of silodosin on detrusor overactivity in the male spontaneously hypertensive rat
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1464-410X.2011.10814.x
https://www.ncbi.nlm.nih.gov/pubmed/22146017
https://www.proquest.com/docview/1350554373
https://search.proquest.com/docview/1022559224
Volume 110
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEB7Eg3jx_aiuEsFrl41JU_boa5GF9SAu7i0kaYqL2op1Qf31zjTdhVUPIt5K06TNTCbzTTP5AnCMLpA7LtNYWdGJZe4M2ZyNE6GUzIQXJ5YCxcG1uhrK_igZNflPtBcm8EPMfriRZdTzNRm4sdVXI5ex5J1RYOLk6N1km_AkFylld13czJik8NH6VMlQBWH7fFLPjw3Ne6pv8HMezdbuqLcKD9OOhCyUh_bk1bbdxxeOx__p6RqsNKiVnYZhtg4LvtiApUGzLr8Jd4EEmZU5q8aPGOlW44KVBcs87ekoXxglitIWCjqpgmEZwk72hL6JUYYu4lNfTqrHd3aPUfFLk1PPcGxuwbB3eXt-FTdHNsQOkZeMkyzv8kxwo2THJR3Jjc28xyAuydLEGcudkM5giUlNbq3sOmKfERZRGrH0eLENi0VZ-F1gGc4c3VykCMmUVEnXemxAKkQkiJKsURHwqXr0c2Dm0HMRjdQkMU0S07XE9FsErakedWOrleYCUWBCFE8RHM2K0cpo6SQIQFNcjLEX4p0IdoL-Zy89obPRcWKLIK21-Ouv0Wf9YX259-ea-7CM95v84RYsolL9AaKkV3tYj_9PfQ4B3g
link.rule.ids 315,783,787,1378,27937,27938,46307,46731
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3JTsMwEB0hkIAL-xJWI3FNVdeOox5ZVZZyQFT0ZsWOIxAlQbSVgK9nJk4rFTggxC2SYyex_TxvnPEbgEM0gdxyGYfKiHooM5sQ5kwYCaVkKpxoGHIU2zeq1ZGX3ahbpQOiszBeH2K84UbIKNdrAjhtSH9FuQwlr3e9FCdH8yZrSChnEP2CUHp6O9aSwnvLvJK-DhL3ybCeH1uatFXfCOgkny0N0vki9Eaf4uNQnmrDganZjy8qj__0rUuwUBFXduRn2jJMuXwFZtvVr_lVuPc6yKzIWP-xh85u_zFnRc5SR8c6ildGsaJ0ioKSVTAsQ-bJntE8MQrSRYrqimG_984e0DF-rcLqGU7PNeicn92dtMIqa0NokXzJMEqzJk8FT5Ss26gueWJS59CPi9I4sonhVkibYEkSJ5kxsmlJgEYYJGok1OPEOkznRe42gaW4eDQzESMrU1JFTeOwAamQlCBRMokKgI_GR794cQ494dRITT2mqcd02WP6LYCd0UDqCq59zQUSwYhUngI4GBcj0Ojvie8ATa4xul9IeQLY8BNg_NAGpUfHtS2AuBzGX7-NPr7slJdbf665D3Otu_a1vr64udqGebynCifegWkcYLeLpGlg9kowfAKnkQX3
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dS8MwED9EYfji90d1agRfOxaTpuzRr-HXhojDvYUmTXGorTgF9a_3rukGUx9EfCvko81dLve75vILwB66QG65jENlRDOUmU3I5kwYCaVkKpzYNxQodrrqtCfP-1G_yn-iszCeH2L8w40so1yvycCf0uyrkctQ8mbfM3Fy9G6ygXhyRiqcuQSQrsdUUli3vFbSt0HcPpnV82NPk67qG_6chLOlP2rPw_1oJD4N5b7x-mIa9uMLyeP_DHUB5irYyg78PFuEKZcvQa1Tbcwvw61nQWZFxoaDBwx1h4OcFTlLHR3qKJ4ZZYrSGQq6qoJhGeJO9ojOiVGKLgJUV7wOH97ZHYbFz1VSPcPJuQK99snN0WlY3dkQWoReMozSrMVTwRMlmzZqSp6Y1DmM4qI0jmxiuBXSJliSxElmjGxZop8RBmEa0fQ4sQrTeZG7dWApLh2tTMSIyZRUUcs47EAqhCQIk0yiAuAj9egnT82hJ0IaqUlimiSmS4nptwDqIz3qyliHmguEgRFxPAWwOy5GM6O9Ey8ATYExBl8IeAJY8_ofv3SfLkfHlS2AuNTir79GH573yseNP7fcgdrVcVtfnnUvNmEWq1S5xHWYRv26LURML2a7NIVPfmQEpg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+silodosin+on+detrusor+overactivity+in+the+male+spontaneously+hypertensive+rat&rft.jtitle=BJU+international&rft.au=Inoue%2C+Seiya&rft.au=Saito%2C+Motoaki&rft.au=Tsounapi%2C+Panagiota&rft.au=Dimitriadis%2C+Fotios&rft.date=2012-07-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=1464-4096&rft.eissn=1464-410X&rft.volume=110&rft.issue=2b&rft.spage=E118&rft.epage=E124&rft_id=info:doi/10.1111%2Fj.1464-410X.2011.10814.x&rft.externalDBID=10.1111%252Fj.1464-410X.2011.10814.x&rft.externalDocID=BJU10814
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1464-4096&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1464-4096&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1464-4096&client=summon